Anavex Life Sciences Corp.
AVXL
$2.75
-$0.10-3.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 246.57% | 6.04% | 42.19% | 25.79% | -18.28% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5,540.76% | -71.64% | -70.25% | -13.95% | 198.41% |
| Change in Net Operating Assets | -71.92% | 122.66% | -3.16% | 29.53% | -191.11% |
| Cash from Operations | -104.86% | 37.91% | 16.89% | 30.97% | -112.84% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -99.69% | 247.19% | 8,691.60% | -86.03% |
| Repurchase of Common Stock | -- | -- | -- | 80.33% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -99.69% | 262.61% | 567.43% | -351.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -110.21% | -114.83% | 1,964.54% | 109.67% | -191.91% |